Physician profile

Carolyn Macuha

Nurse Practitioner · The Villages, FL

NPI 1518592039

$7,681.23

in general payments reported to CMS, 2019-2025

43 companies · $1,698 in 2025

The $1,698 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,637.61

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $952.66 2021-2025 Tepezza, Evenity, Repatha
Novo Nordisk INC $892.40 2021-2025 Wegovy, Ozempic, Rybelsus
Medtronic, INC. $510.81 2021-2025 Minimed 780g
Janssen Biotech, INC. $454.47 2025 Tremfya, Simponi Aria, Simponi
Boston Scientific Corporation $337.95 2023-2025 Watchman Flx
Astrazeneca Pharmaceuticals LP $319.84 2021-2024 Farxiga, Brilinta
Aimmune Therapeutics, INC. $306.85 2024-2025 Zenpep, Vowst
Esperion Therapeutics, INC. $272.80 2021-2023 Nexletol
Merck Sharp & Dohme LLC $252.17 2023 Verquvo
Mannkind Corporation $250.00 2023 V-Go
Dexcom, INC. $248.71 2022-2025 Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor
Corcept Therapeutics $239.50 2021-2022
Abbvie INC. $231.74 2021-2025
Horizon Therapeutics Plc $226.27 2021-2022
Bayer Healthcare Pharmaceuticals INC. $224.73 2022-2023
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $197.84 2021-2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $172.37 2023 Lifevest
Boehringer Ingelheim Pharmaceuticals, INC. $160.07 2022-2023 Jardiance
Phathom Pharmaceuticals, INC. $156.75 2024-2025 Voquezna
Edwards Lifesciences Corporation $153.50 2024 Sapien 3 Ultra Resilia
Xeris Pharmaceuticals, INC. $150.88 2022-2023 Recorlev
Madrigal Pharmaceuticals $138.44 2024-2025 Rezdiffra, Resmetirom
Grt US Holding, INC. $125.30 2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $84.34 2024-2025 Xifaxan, Plenvu
Lexicon Pharmaceuticals, INC. $79.17 2023 Inpefa
Sanofi-Aventis U.S. LLC $74.05 2023
Intercept Pharmaceuticals, INC. $56.28 2024-2025
Exact Sciences Corporation $55.93 2024-2025 Cologuard Collection Kit
Pfizer INC. $55.91 2023
Janssen Pharmaceuticals, INC $44.28 2023 Xarelto
Organon LLC $25.77 2024
Braintree Laboratories, INC. $24.63 2024 Suflave
Ipsen Biopharmaceuticals, INC $24.21 2025 Iqirvo
Teleflex LLC $20.99 2023 Manta
Ardelyx, INC. $19.98 2024 Ibsrela
Takeda Pharmaceuticals U.S.A., INC. $19.67 2025 Eohilia
Novartis Pharmaceuticals Corporation $19.64 2023
Enterra Medical, INC. $19.00 2024
Ironwood Pharmaceuticals, INC $18.33 2024
Kiniksa Pharmaceuticals, LTD. $17.80 2023 Arcalyst
Scpharmaceuticals INC. $17.35 2023
Vivus LLC $14.61 2025 Pancreaze
Amarin Pharma, INC. $13.24 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Carolyn Macuha

$7,681.23

in general payments reported 2019-2025

Years
2021-2025
Top company
Amgen INC.
Context
The $1,698 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

https://glasscript.com/doctor/11024607/carolyn-macuha

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.